<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02042820</url>
  </required_header>
  <id_info>
    <org_study_id>13-149H</org_study_id>
    <nct_id>NCT02042820</nct_id>
  </id_info>
  <brief_title>Ocular Surface Immune Response in Dry Eye Disease</brief_title>
  <official_title>Ocular Surface Immune Response in Dry Eye Disease: Analysis of Conjunctival and Peripheral Corneal Immune Cell Alterations by In Vivo Confocal Microscopy and Clinical Correlation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In vivo confocal microscopy (IVCM) is a sensitive imaging tool for detecting dry&#xD;
      eye-associated subclinical inflammation. Studies have previously shown that IVCM provides an&#xD;
      in vivo metric to measure inflammatory changes in the central cornea. The objective of the&#xD;
      current study is to assess inflammatory response changes in the peripheral cornea and the&#xD;
      conjunctiva by analyzing epithelial immune cell density and morphology in these areas and&#xD;
      then correlating the IVCM findings to clinical signs and symptoms to establish novel&#xD;
      objective imaging biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral Corneal Immune cell Status by IVCM</measure>
    <time_frame>Visit 1</time_frame>
    <description>Peripheral Corneal Immune cell Status by IVCM • Density of dendritic immune cells • Density of non-dendritic immune cells • Morphology of immune cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bulbar conjunctival immune cell Status by IVCM</measure>
    <time_frame>Visit 1</time_frame>
    <description>Bulbar conjunctival immune cell Status by IVCM • Density of dendritic immune cells • Density of non-dendritic immune cells • Morphology of immune cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Parameter: Ocular Surface Disease Index (OSDI)</measure>
    <time_frame>Visit 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Parameter: Schirmer's II test</measure>
    <time_frame>Visit 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Parameter: Conjunctival staining with lissamine green</measure>
    <time_frame>Visit 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Parameter: Corneal staining with fluorescein</measure>
    <time_frame>Visit 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Parameter: Tear Break Up Time (TBUT)</measure>
    <time_frame>Visit 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Parameter: Conjunctival redness</measure>
    <time_frame>Visit 1</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">67</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>Dry Eye Disease</arm_group_label>
    <description>Confocal Imaging - In vivo confocal microscopy (IVCM)&#xD;
Ophthalmic Examination:&#xD;
Tear Break Up Time (TBUT)&#xD;
Ocular Surface Disease Index (OSDI)&#xD;
Schirmer's II test&#xD;
Conjunctival staining with lissamine green&#xD;
Corneal staining with fluorescein&#xD;
Conjunctival redness assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Confocal Imaging - In vivo confocal microscopy (IVCM)&#xD;
Ophthalmic Examination:&#xD;
TBUT&#xD;
OSDI&#xD;
Schirmer's II test&#xD;
Conjunctival staining with lissamine green&#xD;
Corneal staining with fluorescein&#xD;
Conjunctival redness assessment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>In vivo confocal microscopy (IVCM)</intervention_name>
    <description>IVCM is a sensitive tool for detecting dry eye-associated subclinical inflammation.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Dry Eye Disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with and without Dry Eye Disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For Dry Eye Disease Participants&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18&#xD;
&#xD;
          -  Ability to consent to study&#xD;
&#xD;
          -  Symptoms of dry eye disease for at least 6 months, such foreign body sensation,&#xD;
             burning, stinging, light sensitivity&#xD;
&#xD;
          -  Positive vital dye staining of the cornea&#xD;
&#xD;
          -  At least one of the following objective signs: (Schirmer I &lt;10 mm at 5 minutes),&#xD;
             decreased (&lt;0.2 mm) tear meniscus, decreased tear breakup time (TBUT) of &lt;10 seconds,&#xD;
             positive vital dye staining of the conjunctiva&#xD;
&#xD;
        For Age-Match Controls&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Between the ages of 18-89&#xD;
&#xD;
          -  The ability to provide informed consent for study inclusion&#xD;
&#xD;
          -  Clear, healthy cornea&#xD;
&#xD;
          -  Normal tear meniscus (&gt; 0.3 mm)&#xD;
&#xD;
        For Dry Eye Disease Participants&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of contact lens wear in the past 3 months&#xD;
&#xD;
          -  History of ocular surgery in the past 6 months&#xD;
&#xD;
          -  Active ocular allergies&#xD;
&#xD;
          -  History of ocular infection in the past 3 months&#xD;
&#xD;
          -  History of diabetes&#xD;
&#xD;
          -  History of topical or systemic anti-inflammatory therapy in the past 1 month&#xD;
&#xD;
        For Age-Match Controls&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of ocular or eyelid surgery within the past 12 months&#xD;
&#xD;
          -  History of herpetic or other infectious keratitis or other inflammatory eye disease&#xD;
&#xD;
          -  History of any other acute ocular disease&#xD;
&#xD;
          -  Current use of topical medications (not including artificial tears)&#xD;
&#xD;
          -  Current use of contact lenses&#xD;
&#xD;
          -  History of ocular carcinoma or any recent ocular topical chemotherapy or radiotherapy&#xD;
&#xD;
          -  History of cancer elsewhere in the body which is currently under systemic chemotherapy&#xD;
&#xD;
          -  Current glaucoma disease requiring use of glaucoma drops&#xD;
&#xD;
          -  History of Diabetes mellitus&#xD;
&#xD;
          -  Current diagnosis of dry eye disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedram Hamrah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MEEI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>January 17, 2014</study_first_submitted>
  <study_first_submitted_qc>January 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Eye</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

